Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation

Novel Antibodies for Managing Cachexia.

Cachexia is a complex, multifactorial syndrome driven by anorexia and systemic inflammation, ultimately resulting in a catabolic state characterized by weight loss, decreased muscle mass, and impaired physical function. Many chronic comorbidities are implicated in the pathophysiology of cachexia, with malignancy being one of the most common. Although approved cachexia-directed therapies are limited to date, the growth differentiation factor 15 (GDF-15)-glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) signaling axis has been identified as a primary mediator of cachexia and is an interesting pathway for cachexia-directed therapies and antibodies. Ponsegromab, a monoclonal antibody that is a highly selective and potent inhibitor of GDF-15, has resulted in improved body weight and other cachexia-related symptoms in patients with cancer. Other anti-GDF-15 and anti-GFRAL therapies are currently under investigation. Through the development of these treatments, many unexpected potential therapeutic applications have been identified, highlighting the broad, systemic impacts of cachexia. As research continues, it is imperative to focus on clear trial design and endpoints.

The host matters: Integrating resting energy expenditure into personalized medicine beyond tumor-centered approaches.

Systemic Inflammatory Biomarkers and Cancer-Associated Cachexia: A Narrative Review

Simple Summary Cancer-associated cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and poor nutritional intake secondary to anorexia, affecting up to 80% of patients with advanced cancer. Despite its profound impact on survival and quality of life, inconsistent diagnostic criteria and heterogeneity in measurement across research studies limit its translation into routine clinical practice. Inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, C-reactive protein, the neutrophil-to-lymphocyte ratio, and serum albumin, have been widely investigated for their ability to reflect the presence, severity, and progression of cachexia. This review aimed to synthesize current evidence on these key biomarkers to clarify their clinical utility and to support efforts toward standardized assessment, early recognition, and improved monitoring of cancer-associated cachexia.

INTEGRATIVE FRAMEWORK OF PHYSIOTHERAPY TO MANAGE CANCER CACHEXIA USING METABOLOMICS AND PERSONALIZED NUTRITION

Cancer cachexia, a multidimensional, complex metabolic syndrome of involuntary weight loss, muscle wasting, and systemic inflammation, continues to threaten cancer therapy outcomes and survival and quality of life. Traditional physiotherapy and nutrition care often employ nonindividualized methods, disregarding metabolic heterogeneity at the individual level. This study introduces a novel Integrative Physiotherapy Framework (IPF) that integrates metabolomicsguided phenotyping with personalized rehabilitation and nutritional programs to enhance metabolic resilience in cancer cachexia patients. Metabolic signatures defining impaired energy flux, mitochondrial perturbation, and inflammatory dysregulation were defined through untargeted plasma and skeletal muscle metabolomic profiling. These evidence-based individualized physiotherapy treatment regimens consist of resistance and aerobic exercise with omega-3 fatty acid-fortified dietary preparations, branchedchain amino acids, and antiinflammatory plant phytochemicals. In a 12week pilot cohort, the IPF elicited striking increases in lean body mass, muscle strength, and fatigue indices, as well as normalization of important metabolites like lactate, kynurenine, and βhydroxybutyrate. The results show that modulation of individual metabolic phenotypes by physiotherapy-facilitated metabolic modulation can reduce cachexia onset and restore functional capacity. By incorporating metabolomic understanding into clinical rehabilitation, the paradigm provides a precision-medicine treatment model for oncology physiotherapy, integrating molecular science and functional rehabilitation in a synthesis of supportive cancer care that redefines supportive cancer care.

Saudi Journal of Medicine and Public Health

Context-dependent regulation of IL-6 in exercise and colorectal cancer cachexia

Colorectal cancer (CRC) is a common malignancy of the digestive system and remains a major cause of cancer-related morbidity and mortality worldwide. Its development and progression are influenced by genetic susceptibility, lifestyle factors, metabolic dysregulation, and chronic inflammatory states. Cancer cachexia is a multifactorial wasting syndrome characterized by weight loss, skeletal muscle atrophy, metabolic disturbances, and functional decline, which substantially impairs quality of life and survival outcomes in patients with CRC. In this context, interleukin-6 (IL-6) has emerged as a context-dependent regulatory mediator linking inflammation, metabolism, tumor biology, and skeletal muscle wasting. The biological effects of IL-6 are shaped by signaling mode, cellular source, concentration, temporal dynamics, and the broader tumor–host environment. This review discusses the regulatory roles of IL-6 in CRC and CRC-related cachexia, with particular attention to exercise-associated IL-6 responses. Rather than viewing exercise-induced IL-6 as inherently beneficial or antitumor, we emphasize that IL-6 is one component of a broader exercise-responsive network involving metabolic adaptation, immune regulation, skeletal muscle function, and systemic inflammatory remodeling. We also summarize current evidence regarding how exercise modality and intensity may influence IL-6 dynamics, while distinguishing mechanistic and preclinical findings from limited and heterogeneous human data. Overall, IL-6 dynamics may provide a hypothesis-generating framework for understanding exercise responses in CRC-related cachexia, but current evidence is insufficient to support IL-6-guided individualized exercise prescription or therapeutic decision-making in clinical practice.